NV-ARMIS
6.8.2024 14:01:31 CEST | Business Wire | Press release
Black Hat – Armis, the asset intelligence cybersecurity company, announced today that it has surpassed $200m in annual recurring revenue (ARR), doubling its ARR in less than 18 months and making it one of just a few companies that have achieved this rapid scale, not just in the cybersecurity market, but of any SaaS company worldwide.
Armis’ explosive growth has been driven by its award-winning AI-powered cyber exposure management platform, Armis Centrix™, which has been adopted by the world’s leading organizations, including 35 of the top Fortune 100 companies. Customers like United Airlines, the U.S Postal Service, Ryanair, Mondelez, Reckitt and Flex trust Armis to help them secure their most critical environments. Great demand from national, state, local and Federal entities has led to increased deployment of Armis’ solutions globally. Armis also saw continued momentum across North America, EMEA and APJ which has led Armis to double its ARR in less than 18 months.
“This significant milestone reflects not just our huge financial growth in the last year but shows the unwavering trust that Fortune 100, 200, and 500 companies, large private organizations and healthcare systems, and governments place in us to safeguard their mission critical assets & infrastructure,” said Yevgeny Dibrov, Co-Founder and CEO at Armis. “Our commitment to empowering businesses with robust asset intelligence and security, proactive defense strategies and full risk management has never been stronger. As we continue to expand our impact across industries, this milestone fuels our mission to ensure that every organization can operate confidently in the face of evolving threats.”
Armis’ mission is to protect organizations' entire attack surface by managing cyber risk exposure in real time. Its cloud-based platform Armis Centrix™ and its suite of solutions proactively mitigate all cyber asset risks by identifying every asset, from the ground to the cloud, remediating vulnerabilities and blocking threats to give organizations peace of mind that all critical assets are protected.
Demand for Armis’ award-winning platform Armis Centrix™ continues at a rapid pace. Armis has expanded its capabilities & offerings, with the back to back acquisitions earlier this year of CTCI and Silk Security. Armis Centrix™ product suites now include deeper vulnerability mitigation, prioritization, remediation, risk management and threat intelligence. It has developed a world-class partner first approach and seen expansion with some key partnerships over the last few years such as Accenture, Blackwood, Booz Allen Hamilton, CDI, Fortinet, GuidePoint Security, HCl, KPMG, Nomios, Optiv, Presidio, PWC, Softcat, Source IT Technologies, Telia Cygate, WWT and the AWS and Google Marketplaces.
“Over the past year we have been laser focused on efficient growth, expansion of customer engagement, adoption of our platform Armis Centrix™️, its 5 product suites, and have focused more on expanding our channel partner engagement,” said Jonathan Carr, Chief Financial Officer of Armis. “With our recent acquisitions and expanded capabilities, we continue to see high demand for our platform, its products and are growing well in excess of top public company benchmarks, in addition to our own industry peers.”
“Armis is an integral part of Main Line Health’s cybersecurity program, providing unparalleled visibility into every asset and device within our environment,” said Aaron Weismann, Chief Information Security Officer at Main Line Health. “As a hospital system dedicated to delivering safe, high-quality, equitable and affordable care to treat and cure disease, Armis allows us to focus on what truly matters.”
Industry analysts have recognized Armis’ broad platform offering with Frost & Sullivan awarding Armis two Best Practices awards - Customer Value Leadership for OT Cybersecurity and Technology Innovation Leadership for Global Healthcare Cybersecurity.
Additional industry analyst firm recognition:
The Forrester Wave™: Operational Technology Security Solutions, Q2 2024, “Armis is ideally suited for organizations needing to manage a diverse and sprawling IoT and OT environment.”
Manuel Alborez, Frost & Sullivan Best Practices Research Analyst, “The Armis Centrix™ platform’s overarching distinction is that, through a single pane of glass, it provides a real-time, contextual view of the environment and security posture, monitoring and managing all assets affecting patient care, including IT, OT, IoT, medical devices, enterprise assets, and cloud infrastructure. In addition to this robust visibility, Armis offers cutting-edge threat intelligence and forensic monitoring capabilities.”
Danielle VanZandt, Frost & Sullivan Industry Manager – Commercial & Public Security, “In the face of a sprawling IT, OT, and IoT ecosystem, Armis provides its customers with the centralized management needed to protect their businesses. As organizations shift away from network-centric security, Armis acknowledges the potential vulnerability of any asset type. This enables them to guide security teams in proactive mitigation efforts, safeguarding the robustness of essential business processes across various sectors.”
Chris Ray, GigaOm Analyst, “Armis is a formidable player in the ASM landscape, focusing on asset discovery and management. At its core, the platform utilizes a dual-method approach for asset discovery: integration-based discovery for known assets and deep packet inspection (DPI) of network traffic to unearth everything else.”
Additional analyst recognition and awards have been received in the last 12 months and are a testament to Armis’ award-winning Armis Centrix™ platform and approach to customer success:
- Armis is a Leader in two 2024 GigaOm Radar reports: “GigaOm Radar for Attack Surface Management” and “GigaOm Radar for OT Security.”
- Armis won the “2024 Frost & Sullivan Technology Innovation Leadership Award for Global Healthcare Cybersecurity.”
- Armis won the “2024 Frost & Sullivan Customer Value Leadership Award for Operational Technology Cybersecurity.”
- KLAS Research recognized Armis as a Healthcare IoT Security Top Performer in the 2024 Best in KLAS Software & Services.
- Armis is a Leader in the “Frost Radar for Operational Technology Cybersecurity Solutions, 2023.”
- Armis is named a Representative Vendor in three 2023 Gartner Market Guides: “Market Guide for Vulnerability Assessment,” “Market Guide for CPS Protection Platforms,” and “Market Guide for Medical Device Security.”
Recent awards in the last year are as follows:
- Inc.’s 2024 Best Workplaces List
- 2024 Cybersecurity Excellence Awards
- Cyber Defense Magazine's 2024 Global InfoSec Awards
- 2024 Cloud Security Awards
- CRN Security 100 2024
- CRN Internet of Things 50 2024
- CRN Partner Program Guide 2024
- Fast Company’s Most Innovative Companies 2023
- EY Entrepreneur of The Year 2023 Bay Area Winner; Armis CEO and Co-Founder, Yevgeny Dibrov
- 2023 ‘ASTORS’ Awards - Platinum Award Winner
- 2023 Inc. 5000
- Deloitte Technology Fast 500 2023
About Armis
Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization’s cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets – from the ground to the cloud. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240806677978/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
